Major histocompatibility complex class I – T-cell receptor complex (MHC class I–TCR complex)

The **major histocompatibility complex class I – T-cell receptor (MHC class I–TCR) complex** is a transient, highly specific molecular assembly formed during the immune response between a cytotoxic T lymphocyte and a target cell. The **class I MHC molecule**, present on nearly all nucleated cells, binds endogenous peptides (usually 8–10 amino acids) in its peptide-binding groove and presents them on the cell surface. The **T cell receptor** (usually on cytotoxic CD8+ T cells) recognizes this peptide–MHC complex through direct, highly variable molecular interactions, initiating T cell activation and cytotoxic activity if the peptide is non-self or aberrant[1][3][5][6][7][8]. This recognition drives adaptive immunity against infected or malignant cells and is central to immunosurveillance and immune elimination of threats. **Clarifications and assessment:** - This is a *complex* (the interface between MHC class I, its bound peptide, and the T cell receptor) rather than a single molecule or a canonical drug target in the usual sense. Both MHC class I and TCR are individually established immunological targets/receptors, but their complex is transient and not a classical drug target per se. For most therapeutic/biological purposes, **MHC class I** or **T cell receptor** would be the canonical entities, not the complex. - Some immunotherapies (notably immune checkpoint inhibitors) indirectly modulate the outcome of the TCR–MHC engagement, while advanced cellular therapies (like TCR-engineered T cells) are designed for specific pMHC recognition. **Summary:** The **MHC class I–TCR complex** is foundational for T cell–mediated immunity, enabling cytotoxic T cells to detect and respond to infected or transformed cells by recognizing specific peptides presented by MHC class I molecules. However, as a target designation, this "complex" is not a canonical single therapeutic target; rather, it represents the interface critical for adaptive immunity and targeted by several immunotherapeutic strategies[3][7][8].

Other names

MHC class I–TCRpeptide-MHC–TCR complexpMHC–TCR complex

Blockade of inhibitory signaling to enhance T cell activation; Engineering of TCR specificity to target malignant or infected cells.